Citations

Mayo Clinic

Showing 10 of 108523 citations.

CD19-directed CART therapy for T-cell/histiocyte–rich large B-cell lymphoma
Pophali, Priyanka A. , Ahn, Kwang Woo , Allbee-Johnson, Molly, Ahmed, Nausheen , Awan, Farrukh T. , Farhan, Shatha , Grover, Natalie S. , Hilal, Talal , Modi, Dipenkumar , Nasrollahi, Elham , Schachter, Levanto , Sauter, Craig S. , Herrera, Alex F. , Ahn, Kwang W , Ahmed, Nausheen , Awan, Farrukh T , Farhan, Shatha , Grover, Natalie S , Hilal, Talal , Modi, Dipenkumar , Hamadani, Mehdi , Herrera, Alex F , Shadman, Mazyar , Pophali, Priyanka , Fein, Joshua Alexander , Iqbal, Madiha , Maakaron, Joseph E. , Hamadani, Mehdi , Shouval, Roni , Shadman, Mazyar

Blood Advances | July 10, 2024 | Volume: 8 | Issue: 20 | Pages: 5290-5296

10.1182/bloodadvances.2024013863 | PMID 38985302 Get It

Abstract T-cell/histiocyte–rich large B-cell lymphoma (THRLBCL) is a rare histologic variant of LBCL. Limited data regarding CD19–directed chimeric antigen receptor T-cell (CART) therapy in relapsed/refractory (R/R) THRLBCL suggest poor efficacy. We investigated CART outcomes for R/R THRLBCL through the Center for International Blood and Marrow Transplant Research registry. A total of 58 adult patients with R/R THRLBCL who received commercial CD19-CART therapy between 2018 and 2022 were identified. Most patients (67%) had early relapse of disease (45% primary refractory) with a median of 3 (range, 1-7) prior therapies and were treated with axicabtagene ciloleucel (69%). At median follow-up of 23 months after CART therapy, 2-year overall and progression-free survival were 42% (95% confidence interval [CI], 27-57) and 29% (95% CI, 17-43), respectively. In univariable analysis, poor performance status before CART therapy was associated with higher mortality (hazard ratio, 2.35; 95%CI, 1.02-5.5). The 2-year cumulative incidences of relapse/progression and nonrelapse mortality were 69% and 2%, respectively. Grade ≥3 cytokine release syndrome and immune effector cell–associated neurologic syndrome occurred in 7% and 15% of patients, respectively. In this largest analysis of CD19-CART therapy for R/R THRLBCL, ∼30% of patients were alive and progression free 2 years after CART therapy. Despite a high incidence of progression (69% at 2 years), these results suggest a subset of patients with R/R THRLBCL may have durable responses with CARTs.
A phase 2 study of a brachyury‐targeting vaccine in combination with radiation therapy for the treatment of advanced chordoma
Attia, Steven , Tine, Brian A. Van , Seetharam, ­Mahesh , Gafoor, Zarina, Heery, Christopher R., Pico-Navarro, Cesar, Adams, Tatiana , Van Tine, Brian A , Coté, Gregory M. , Conley, Anthony P. , Chen, Yen‐Lin

Cancer | July 10, 2024 | Volume: 130 | Issue: 22 | Pages: 3845-3854

10.1002/cncr.35477 | PMID 38985843 Get It

AbstractBackgroundThis was a single‐arm, phase 2 clinical trial of Bavarian Nordic (BN)‐Brachyury vaccine plus radiotherapy (RT) designed to determine the objective response rate (ORR), progression‐free survival (PFS), and safety of the combination in chordoma.MethodsA total of 29 adult patients with advanced chordoma were treated with two subcutaneous priming vaccine doses of modified vaccinia Ankara‐Bavarian Nordic (MVA‐BN)‐Brachyury and one vaccine dose of fowlpox virus (FPV)‐Brachyury before RT. After RT, booster vaccinations were given with FPV‐Brachyury every 4 weeks for 4 doses, then every 12 weeks (week 110). A minimum RT dose of >8 Gy in one fraction for each target was required. Response was evaluated by modified Response Evaluation Criteria in Solid Tumors 1.1 (mRECIST), where only radiated lesions were considered targets, and by standard RECIST 1.1 in a subset of patients.ResultsTwo of 26 evaluable patients experienced durable partial response (PR) (ORR of 7.7%; 90% confidence interval [CI], 2.6–20.8]) by mRECIST 1.1. A total of 21 patients (80.8%; 90% CI, 65.4–90.3) had stable disease, and three patients (11.5%; 90% CI, 4.7–25.6) had progressive disease as best response per mRECIST 1.1. Median PFS was not reached during the study.ConclusionsThis trial confirms the safety of BN‐Brachyury and RT. Although the study did not meet the predefined study goal of four responses in 29 patients, we did observe two PRs and a PFS of greater than 2 years. For a vaccine‐based study in chordoma, an ultra‐rare disease where response rates are low, a randomized study or novel trial designs may be required to confirm activity.
Tailoring neoadjuvant systemic therapy in breast cancer: “The advent of a personalized approach”—The Breast‐Gynecological and Immuno‐Oncology International Cancer Conference (BGICC) consensus and recommendations
Elghazaly, Hesham , Azim, Hamdy A., Curigliano, Giuseppe , Tripathy, Debu , Arun, Banu , Aapro, Matti , Piccart, Martine , Elghazawy, Hagar , Saghir, Nagi S. El , Perez, Edith A. , Poortmans, Philip , Abdel-Aziz, Hany, El‐Zawahry, Heba M., Sabry, Mohamed , Viale, Giuseppe , Gado, Neven, Leung, James , El-Arab, Lobna Ezz, Cardoso, Maria João , Al‐Foheidi, Meteb , ElMaadawy, Merit, Selim, Ashraf S. M., Kandil, Alaa , Kamal, Rasha Mohammed, Guarneri, Valentina , Abulkhair, Omalkhair , Zakaria, Omar, Golshan, Mehra, Orecchia, Roberto , El-Mahdy, Manal Mohamed, Abdel‐Aziz, Ahmed M., Eldin, Nermean Bahie, Curigliano, Giuseppe , Arun, Banu , Gligorov, Joseph , Elghazawy, Hagar I , El Saghir, Nagi S , Perez, Edith A , Conte, Pierfranco , Tripathy, Debasish , Rugo, Hope S. , Cameron, David , Swain, Sandra M. , Harbeck, Nadia , Cardoso, Fátima , Gligorov, Joseph , Penault-Llorca, Frederique Madeleine , Kassem, Loay Mohamed Hassan , Al‐Sukhun, Sana , Abdelkarim, Khaled , Conte, PierFranco , Selim, Ashraf S. M. , Палтуев, Руслан Маликович , Abdel‐Aziz, Ahmed M.

Cancer | July 10, 2024 | Volume: 130 | Issue: 19 | Pages: 3251-3271

10.1002/cncr.35389 | PMID 38985794 Get It

AbstractBackgroundThe management of early breast cancer (BC) has witnessed an uprise in the use of neoadjuvant therapy and a remarkable reshaping of the systemic therapy postneoadjuvant treatment in the last few years, with the evolution of many controversial clinical situations that require consensus.MethodsDuring the 14th Breast‐Gynecological and Immuno‐Oncology International Cancer Conference held in Egypt in 2022, a panel of 44 BC experts from 13 countries voted on statements concerning debatable challenges in the neo/adjuvant treatment setting. The recommendations were subsequently updated based on the most recent data emerging. A modified Delphi approach was used to develop this consensus. A consensus was achieved when ≥75% of voters selected an answer.Results and ConclusionsThe consensus recommendations addressed different escalation and de‐escalation strategies in the setting of neoadjuvant therapy for early BC. The recommendations recapitulate the available clinical evidence and expert opinion to individualize patient management and optimize therapy outcomes. Consensus was reached in 63% of the statements (52/83), and the rationale behind each statement was clarified.
Adverse event costs of systemic therapies for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy and biologics in the US
Paly, Victoria Federico , Bekaii‐Saab, Tanios , Padukkavidana, Thihan, Hernández, Luis , Hernandez, Luis , Bekaii-Saab, Tanios S , Dasari, Arvind , Hubbard, Joleen M.

Journal of Comparative Effectiveness Research | July 10, 2024 | Volume: 13 | Issue: 8 | Pages: No page available

10.57264/cer-2024-0084 | PMID 38976346 Get It

Aim: The objective of this study was to compare adverse event (AE) management costs for fruquintinib, regorafenib, trifluridine/tipiracil (T/T) and trifluridine/tipiracil+bevacizumab (T/T+bev) for patients with metastatic colorectal cancer (mCRC) previously treated with at least two prior lines of therapy from the US commercial and Medicare payer perspectives. Materials & methods: A cost-consequence model was developed to calculate the per-patient and per-patient-per-month (PPPM) AE costs using rates of grade 3/4 AEs with incidence ≥5% in clinical trials, event-specific management costs and duration treatment. Anchored comparisons of AE costs were calculated using a difference-in-differences approach with best supportive care (BSC) as a common reference. AE rates and treatment duration were obtained from clinical trials: FRESCO and FRESCO-2 (fruquintinib), RECOURSE (T/T), CORRECT (regorafenib) and SUNLIGHT (T/T, T/T+bev). AE management costs for the commercial and Medicare perspectives were obtained from publicly available sources. Results: From the commercial perspective, the AE costs (presented as per-patient, PPPM) were: $4015, $1091 for fruquintinib (FRESCO); $4253, $1390 for fruquintinib (FRESCO-2); $17,110, $11,104 for T/T (RECOURSE); $9851, $4691 for T/T (SUNLIGHT); $8199, $4823 for regorafenib; and $11,620, $2324 for T/T+bev. These results were consistent in anchored comparisons: the difference-in-difference for fruquintinib based on FRESCO was -$1929 versus regorafenib and -$11,427 versus T/T; for fruquintinib based on FRESCO-2 was -$2257 versus regorafenib and -$11,756 versus T/T. Across all analyses, results were consistent from the Medicare perspective. Conclusion: Fruquintinib was associated with lower AE management costs compared with regorafenib, T/T and T/T+bev for patients with previously treated mCRC. This evidence has direct implications for treatment, formulary and pathways decision-making in this patient population.
Dopamine Dressing: AJR Podcast Series on Wellness, Episode 4
Wang, Sherry S.

American Journal of Roentgenology | July 10, 2024 | Volume: 223 | Issue: 2 | Pages: No page available

10.2214/ajr.24.31697 | PMID 38984782 Get It

Training and Verification Requirements for Interpretation of Cardiac CT and MRI: AJR Expert Panel Narrative Review
Morris, Michael F. , Ocazionez-Trujillo, Daniel , Ordovás, Karen , Ranganath, Praveen , Vargas, Daniel , Woodard, Pamela K. , Choi, Andrew , Rajiah, Prabhakar Shantha, Rajiah, Prabhakar , Budoff, Matthew J. , Ghoshhajra, Brian , Patel, Amit R.

American Journal of Roentgenology | July 10, 2024 | Volume: 224 | Issue: 3 | Pages: No page available

10.2214/ajr.24.31524 | PMID 38984783 Get It

Percutaneous Aspiration and Sclerotherapy as Primary Management for a Symptomatic Benign Adrenal Cyst
Strikwerda, John R. , McKenzie, Travis J. , Foster, Trenton R. , Bancos, Irina , Foster, Trenton R , Thompson, Scott M. , Shah, Mithun V , Bancos, Irina

JCEM Case Reports | July 10, 2024 | Volume: 2 | Issue: 7 | Pages: No page available

10.1210/jcemcr/luae110 | PMID 38989269 Get It

Abstract Adrenal cysts are a rare benign adrenal pathology. Although the majority of adrenal cysts are asymptomatic, large cysts may present with debilitating symptoms of mass effect. Surgical adrenalectomy or cyst fenestration has been the primary mode of management for such symptomatic cysts, but these interventions can be associated with excessive morbidity, particularly when considered in the context of benign disease. Here, we present a case of a 34-year-old female with a longstanding, growing, benign left adrenal cyst associated with nonspecific abdominal symptoms. After multidisciplinary discussion, the patient was managed with primary ultrasound/fluoroscopic guided percutaneous sclerotherapy of her adrenal cyst. This technique achieved complete cyst resolution that was durable on 7-month follow-up and was associated with significant improvement of the patient's symptoms. This case illustrates the potential for primary percutaneous sclerotherapy for primary management of benign adrenal cysts.
Gyratory seizures as a manifestation of possible generalized epilepsy
Ortiz‐Guerrero, Gloria , Ortiz, Judit Perez , Saify, Mariya , Selcen, Duygu , Fine, Anthony L. , Perez-Ortiz, Judit M, Fine, Anthony , Ortiz-Guerrero, Gloria

Epileptic Disorders | July 10, 2024 | Volume: 26 | Issue: 5 | Pages: 718-720

10.1002/epd2.20247 | PMID 38984496 Get It

Content available: Video
Fibula Free Flap Reconstruction of Cervical Spine Defects: A Multi‐Institutional Study
Yang, Sara , Morton, Zoey , Colcord, Maddie, Moore, Eric J. , Thuener, Jason E. , Bewley, Arnaud F. , Coughlin, Andrew, Richmon, Jeremy D. , Pipkorn, Patrik , Zender, Chad , Wax, Mark K. , Moore, Eric J , Thuener, Jason , Richmon, Jeremy D , Zender, Chad A , Wax, Mark K , Jackson, Ryan S. , Khariwala, Samir S , Winters, Ryan D. , Militsakh, Oleg N. , III, James M. Wright

The Laryngoscope | July 10, 2024 | Volume: 134 | Issue: 12 | Pages: 4923-4928

10.1002/lary.31625 | PMID 38984420 Get It

IntroductionCervical spine defects result in spinal instability, putting the spinal cord and vertebral arteries at risk of damage and possibly devastating neurological injuries. The fibula free flap can span the spinal defects for stability. There is a paucity of literature on this technique.MethodMulti‐institutional retrospective case series reviewing patients who underwent cervical spine reconstruction with a fibula free flap. Patient demographic information, comorbidities, characteristics of cervical spine defects, and free flap complications were collected.ResultsA total of 1187 fibula free flaps across 10 different institutions were reviewed. Thirteen patients (1.09%) underwent cervical spine reconstruction with a fibula free flap. Average age was 52.3 years old with an age range of 12–79 years. There were six males (46.1%) and seven females (53.8%). The most common defect etiology was infection (n = 6, 46.1%). Most commonly involved cervical spine level of the defect was C5 (n = 10) followed by C6 (n = 9) and C4 (n = 8). The majority of reconstructed defects spanned three or more cervical levels, (n = 9, 69.2%). Facial artery was the most common arterial anastomosis (n = 8). Eight patients (61.5%) required a tracheostomy during their postoperative course. None of the patients had symptomatic or radiographic nonunion.ConclusionThis case series demonstrates that a vascularized fibula flap is a potential reconstructive option for cervical spine defects, especially in defects greater than three cervical levels, in the setting of infection, and previously radiated patients.Level of Evidence4 Laryngoscope, 134:4923–4928, 2024
Toxic epidermal necrolysis‐like cutaneous toxicity following chimeric antigen receptor T‐cell therapy in recurrent large B‐cell lymphoma
Bhullar, Puneet , Zieman, Daniel, Johnson, Cassandra, Gurnani, Pooja , Sokumbi, Olayemi , Bhullar, Puneet K , Motaparthi, Kiran , Zieman, Daniel P, Sokumbi, Olayemi

Journal of Cutaneous Pathology | July 10, 2024 | Volume: 51 | Issue: 10 | Pages: 767-772

10.1111/cup.14687 | PMID 38982730 Get It

AbstractChimeric antigen receptor (CAR) T‐cell therapy has demonstrated remarkable success in treating various B‐cell malignancies, redirecting T‐cell cytotoxicity toward cancer cells. Despite its efficacy, CAR‐T therapy is associated with potential risks, including cytokine release syndrome (CRS) and cytopenia. We present a case of a 69‐year‐old man with diffuse large B‐cell lymphoma treated with axicabtagene‐ciloleucel CAR‐T therapy, who developed a rare and severe cutaneous toxicity resembling toxic epidermal necrolysis (TEN). The patient exhibited persistent fevers, CRS, and subsequent development of a widespread erythematous macular eruption, progressing to vesiculation with bullae. Notably, allopurinol‐induced TEN was considered with the patient's recent exposure to allopurinol, although the onset and minimal mucosal involvement did not align with typical presentations of allopurinol‐induced cases. The cutaneous reaction, distinct from typical SJS/TEN, showed minimal mucosal involvement and coincided with the cytokine release storm, differing from allopurinol‐induced TEN. Despite the absence of guidelines, the patient was managed with systemic steroids, achieving significant improvement. This case expands the spectrum of CAR‐T therapy‐related cutaneous toxicities, highlighting the need for early recognition of histopathology and tailored management by dermatologists. Further understanding of these reactions is crucial for optimizing the safety profile of this groundbreaking immunotherapy.